Therapy for Treatment of Myelodysplastic Syndrome (MDS)
IRAK1 is a drugable target for treatment of MDS, and IRAK1/BCL2 inhibitors synergistically co-treat MDS.
MDS results from expansion of defective hematopoietic stem cells. There is a need to develop targeted therapies capable of eliminating the defective MDS clones. Dr. Starczynowski has identified that IRAK1, an immune modulating kinase, is overexpressed and hyperactivated in MDS. MDS-propagating clones treated with a small-molecule IRAK1 inhibitor exhibited impaired expansion and increased apoptosis, which coincides with TRAF6/NF-κB inhibition. This indicates that IRAK1 is necessary for survival, proliferation, and NF-κB activation in MDS clones. Dr. Starczynowski has shown that treating with an IRAK1 inhibitor or co-treating with IRAK1 and BCL2 inhibitors eliminate MDS clones with more selectivity and efficiency.
- Therapeutic target for treatment of MDS
- Combination therapy for treatment of MDS
- Increased efficiency of treatment
- Increased selectivity of treatment
Approximately 12,000 people in the United States are diagnosed with MDS each year. The average annual cost of treating MDS symptoms is estimated at more than $63,000 per patient.
Daniel Starczynowski, PhD, Division of Experimental Hematology and Cancer Biology